EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanism of Lian-Huo-Hua-Zhuo Formula in Alleviating Gastric Mucosal Inflammation in a Mouse Model of Chronic Atrophic Gastritis by Inhibiting the IL-17 Signaling Pathway

Xiaoxuan Mo, Fan Gao, Jiaye Tian, Fengyue Xu, Zeyang Xie, Hongyan Wei, Jinhu Yang, Jianming Jiang, Guoxing Deng, Qiuhong Guo

Pharmaceuticals · 05.07.2026 · 19 (7) · 1043

DOI: 10.3390/ph19071043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 05.07.2026. Verfasst von Xiaoxuan Mo und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Provincial Natural Science Foundation, Natural Science Foundation of Hebei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic atrophic gastritis (CAG) is a prevalent precancerous gastric disorder characterized by persistent inflammation, glandular atrophy, and progressive mucosal damage, for which effective multi-target therapeutic strategies remain insufficient. The Lian-Huo-Hua-Zhuo formula (LHHZ), a traditional Chinese herbal prescription, has demonstrated potential anti-inflammatory and gastrointestinal protective effects in clinical practice; however, its active constituents and mechanisms of action against CAG remain undefined. This study aimed to clarify the absorbed bioactive components of LHHZ and explore its therapeutic mechanism for CAG.

Methods

Ultra-high-performance liquid chromatography coupled with quadrupole Orbitrap high-resolution mass spectrometry was employed to identify the absorbed components of LHHZ in the gastric and intestinal tissues of mice. The therapeutic effects of LHHZ on CAG were assessed through histopathological staining, ultrastructural observation, and evaluation of serum and gastric functional indicators. Network pharmacology, molecular docking, and molecular dynamics simulations were integrated to predict the core targets and key signaling pathways, while the regulatory effects on the interleukin-17 (IL-17) signaling pathway were further validated by immunofluorescence staining, real-time quantitative polymerase chain reaction, and Western blotting. Additionally, 16S ribosomal RNA gene sequencing and targeted metabolomics were applied to investigate the effects of LHHZ on gut microbiota composition and short-chain fatty acid (SCFA) metabolism.

Results

The results revealed that 55 and 48 absorbed components were identified in the gastric and intestinal tissues, respectively, predominantly derived from Coptis chinensis Franch. and Pogostemon cablin (Blanco) Benth. LHHZ significantly alleviated gastric mucosal lesions, reduced intestinal metaplasia, restored the ultrastructure of gastric mucosal cells, improved gastric functional indicators including pepsinogen I (PG I), pepsinogen II (PG II), and gastrin-17 (GAS-17), and decreased the levels of pro-inflammatory cytokines. Network pharmacology combined with in vitro and in vivo experiments demonstrated that the core bioactive components of LHHZ can target and regulate interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), attenuate activation of the IL-17 signaling pathway, and suppress the secretion of downstream pro-inflammatory factors. Furthermore, LHHZ enhanced the alpha diversity of gut microbiota, reduced the Firmicutes to Bacteroidetes (F/B) ratio, restored the abundance of SCFA-producing bacteria such as Bacteroidales and Oscillospirales, and normalized the aberrant levels of eight SCFAs. Significant correlations were also observed between gut microbiota composition and SCFA metabolism.

Conclusions

These findings suggest that LHHZ alleviates CAG by inhibiting inflammation via the IL-17 signaling pathway and by modulating the gut microbiota–SCFA axis, thereby providing preclinical evidence supporting its further investigation and development for multi-target therapeutic strategies against CAG.

Schlagwörter

Stichwörter der Autor:innen

IL-17 pathwayLian-Huo-Hua-Zhuo formulachronic atrophic gastritisgut microbiotashort-chain fatty acids

Autor:innen und Institutionen

  • School of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China.
  • Hebei Technology Innovation Center of TCM Formula Preparations, Shijiazhuang 050200, China.

Förderung

  • Hebei Provincial Natural Science Foundation
  • Natural Science Foundation of Hebei Province

Zitieren

APA

Mo, X., Gao, F., Tian, J., Xu, F., Xie, Z., Wei, H., Yang, J., Jiang, J., Deng, G., & Guo, Q. (2026). Mechanism of Lian-Huo-Hua-Zhuo Formula in Alleviating Gastric Mucosal Inflammation in a Mouse Model of Chronic Atrophic Gastritis by Inhibiting the IL-17 Signaling Pathway. Pharmaceuticals, 19(7), 1043. https://doi.org/10.3390/ph19071043

Vancouver

Mo X, Gao F, Tian J, Xu F, Xie Z, Wei H, et al. Mechanism of Lian-Huo-Hua-Zhuo Formula in Alleviating Gastric Mucosal Inflammation in a Mouse Model of Chronic Atrophic Gastritis by Inhibiting the IL-17 Signaling Pathway. Pharmaceuticals. 2026;19(7):1043. doi:10.3390/ph19071043

BibTeX
@article{Mo2026,
  author = {Mo, Xiaoxuan and Gao, Fan and Tian, Jiaye and Xu, Fengyue and Xie, Zeyang and Wei, Hongyan and Yang, Jinhu and Jiang, Jianming and Deng, Guoxing and Guo, Qiuhong},
  title = {Mechanism of Lian-Huo-Hua-Zhuo Formula in Alleviating Gastric Mucosal Inflammation in a Mouse Model of Chronic Atrophic Gastritis by Inhibiting the IL-17 Signaling Pathway},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1043},
  doi = {10.3390/ph19071043}
}
Kostenlos starten →